Where do we stand with mCRPC?

Share :
Published: 25 Oct 2023
Views: 1872
Dr Neal Shore, Prof Neeraj Agarwal, Dr Pasquale Rescigno and Dr Friederike Schlurmann

Dr Neal Shore (Carolina Urologic Research Center, Myrtle Beach, USA), Prof Neeraj Agarwal (University of Utah, Utah, United States), Dr Pasquale Rescigno (Istituto di Candiolo IRCCS (Candiolo Cancer Institute), Candiolo, Italy) and Dr Friederike Schlurmann (Centre Hospitalier Universitaire de Brest, France) discuss the recent updates in mCRPC.

The panel initially discusses who, when and how to test for genetic mutations in prostate cancer. They further cover the PSMAfore data and Dr Agarwal gives an update on the latest from the CONTACT-02 study.

The panel also gives their thoughts on PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor.

The panel also covers the most interesting data from ESMO, ASCO GU and ASCO 2023.


This programme has been supported by an unrestricted educational grant from AstraZeneca.